Azitra

AZTRPhase 2

Azitra is a clinical-stage biopharmaceutical company focused on creating novel therapeutics for skin diseases through microbial and protein engineering. Its core technology platform includes a library of approximately 1,500 unique bacterial strains, augmented by AI/ML and licensed genetic engineering tools, to develop engineered strains of Staphylococcus epidermidis and therapeutic proteins. The company's pipeline targets high-need conditions like Netherton syndrome, EGFR inhibitor-associated rash, and ichthyosis vulgaris, positioning it at the forefront of the emerging live biotherapeutic product field in dermatology.

Market Cap

$4.5M

Focus

BiologicsMicrobiome

AZTR · Stock Price

USD 0.28987.72 (-99.97%)

Historical price data

AI Company Overview

Technology Platform

A proprietary platform combining a library of ~1,500 unique bacterial strains, AI/ML screening tools, and licensed genetic engineering technology to develop engineered live biotherapeutic products and proteins for dermatological conditions.

Pipeline Snapshot

3 drugs in pipeline

Drug	Indication	Stage
ATR-04	Epidermal Growth Factor	Phase 1/2
ATR04-484 + Vehicle	EGFR Inhibitor-associated Rash	Phase 1/2
ATR12-351	Netherton Syndrome	Phase 1

Funding History

Total raised: $26M

IPO$15MUndisclosedJul 15, 2023

Series A$8.5MUndisclosedJun 15, 2018

Seed$2.5MUndisclosedJun 15, 2016

Opportunities

Significant opportunities exist in addressing the high unmet need in rare genetic skin diseases like Netherton syndrome (orphan drug potential) and the large, underserved market for managing severe side effects of widely used EGFR inhibitor cancer drugs.

The platform's flexibility also allows for expansion into other prevalent inflammatory skin conditions.

Risk Factors

Key risks include clinical trial failure of its novel engineered microbe candidates, the need for substantial additional capital to fund development, navigating an uncertain regulatory pathway for live biotherapeutic products, and future competition from other novel therapies.

Competitive Landscape

Azitra competes in the emerging live biotherapeutic product space, differentiating itself through a focus on engineered commensal bacteria for topical dermatology. Competitors range from other microbiome-focused biotechs to large pharmaceutical companies with systemic biologics for inflammatory skin diseases.